|
Acromegaly
|
0.020 |
Biomarker
|
disease |
BEFREE |
As growth hormone (GH) and triiodothyronine (T<sub>3</sub>) increase both GFR and CysC (increased in acromegaly and hyperthyroidism) in vivo, we studied whether they could increase CysC production in 3T3-L1 adipocytes in vitro.
|
30543877 |
2019 |
|
Acromegaly
|
0.020 |
Biomarker
|
disease |
BEFREE |
To measure the severity and extent of CAD in patients with ACRO and to determine whether either EAT or Cys-C reflect higher cardiovascular risk in patients with ACRO than in healthy controls.
|
27910111 |
2017 |
|
Acute Chest Syndrome
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Serum CysC levels could reflect the severity of vascular lesions in ACS patients, and a high CysC level had predictive value regarding the severity of vascular lesions in ACS.
|
28143410 |
2017 |
|
Acute Chest Syndrome
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
This study was performed to investigate the relationship between the serum cystatin C (Cys C) level and acute coronary syndrome (ACS) in patients of advanced age.
|
30871390 |
2019 |
|
Acute Chest Syndrome
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to assess the efficacy of high-dose atorvastatin on the prevention of contrast-induced nephropathy (CIN) in patients with acute coronary syndrome (ACS) undergoing percutaneous intervention and observe the incidence of cystatin C (CyC)-based CIN.
|
29343076 |
2018 |
|
Acute Confusional Senile Dementia
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.
|
18026100 |
2007 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.
|
17192785 |
2007 |
|
Acute Confusional Senile Dementia
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.
|
17192785 |
2007 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.
|
18026100 |
2007 |
|
Acute Coronary Syndrome
|
0.160 |
Biomarker
|
disease |
BEFREE |
Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome.
|
28143410 |
2017 |
|
Acute Coronary Syndrome
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to assess the efficacy of high-dose atorvastatin on the prevention of contrast-induced nephropathy (CIN) in patients with acute coronary syndrome (ACS) undergoing percutaneous intervention and observe the incidence of cystatin C (CyC)-based CIN.
|
29343076 |
2018 |
|
Acute Coronary Syndrome
|
0.160 |
Biomarker
|
disease |
BEFREE |
Conclusions Cys-C is associated with the risk of adverse outcomes in patients after acute coronary syndrome.
|
30371283 |
2018 |
|
Acute Coronary Syndrome
|
0.160 |
Biomarker
|
disease |
BEFREE |
The addition of cystatin C or biomarkers of tubular injury did not meaningfully improve the prediction of eGFR decline beyond common clinical factors and routine laboratory data in a large cohort of patients with type 2 diabetes and recent acute coronary syndrome.
|
29339356 |
2018 |
|
Acute Coronary Syndrome
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.
|
24952865 |
2014 |
|
Acute Coronary Syndrome
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.
|
24952865 |
2014 |
|
Acute Coronary Syndrome
|
0.160 |
AlteredExpression
|
disease |
BEFREE |
Association of serum cystatin C levels with acute coronary syndrome in patients of advanced age.
|
30871390 |
2019 |
|
Acute disease of cardiovascular system
|
0.010 |
Biomarker
|
group |
BEFREE |
The exposure variable used was eGFR level (CKD-EPI based on creatinine and cystatin C) with eGFR 60-89 mL/min/1.73 m<sup>2</sup> as a reference; the outcomes were mortality, acute cardiovascular disease, congestive heart failure, and rapid kidney function decline (RKFD; defined as a decline in eGFR by 3 mL/min/1.73 m<sup>2</sup> per year or more).
|
30560432 |
2019 |
|
Acute heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
Seven circulating biomarkers [NT-proBNP, high sensitivity cardiac troponin T (hs-cTnT), soluble ST2 (sST2), growth differentiation factor 15 (GDF-15), cystatin-C, galectin-3, and high sensitivity C-reactive protein (hs-CRP)] were measured at baseline and on days 2, 5, 14, and 60 in 1161 patients enrolled in the RELAX-AHF trial.
|
28133908 |
2017 |
|
Acute heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Plasma Cystatin C levels do not adequately predict AKI in patients with AHF.
|
28756070 |
2017 |
|
Acute heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
Identification of patients at increased risk of renal dysfunction by assessing cystatin C may enable more tailored therapy, minimizing the incidence of CRS and its negative impact on outcome in AHF.
|
28826934 |
2017 |
|
Acute Inflammatory Demyelinating Polyneuropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three differentially expressed proteins were identified, including the upregulated haptoglobin (Hp) and heat shock protein 70 (Hsp70), and downregulated cystatin C. There were no significant differences between the AIDP and AMAN patients in the positive rates and quantitative expression levels of the three differentially expressed proteins.
|
29904402 |
2018 |
|
Acute kidney injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers.
|
28885000 |
2017 |
|
Acute kidney injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Decrease in urinary creatinine in acute kidney injury influences diagnostic value of urinary biomarker-to-creatinine ratio in rats.
|
22005293 |
2011 |
|
Acute Kidney Insufficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
Decrease in urinary creatinine in acute kidney injury influences diagnostic value of urinary biomarker-to-creatinine ratio in rats.
|
22005293 |
2011 |
|
Acute Kidney Insufficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers.
|
28885000 |
2017 |